Janssen Collaborates with Vifor Pharma to Co-commercialize Invokana (canagliflozin) for the Treatment of Diabetic Kidney Disease in the US

 Janssen Collaborates with Vifor Pharma to Co-commercialize Invokana (canagliflozin) for the Treatment of Diabetic Kidney Disease in the US

Janssen Collaborates with Vifor Pharma to Co-commercialize Invokana (canagliflozin) to Treat Diabetic Kidney Disease in the US

Shots:

  • Vifor and Janssen collaborated to jointly commercialize Invokana (canagliflozin) to treat DKD and to reduce the risk of hospitalization for heart failure in patients with T2D and DKD in the US
  • The Vifor Pharma will utilize it salesforce to promote Invokana to nephrologists which further supports its goal of becoming a leader in nephrology and brings its nephrology portfolio up to twelve products
  • Invokana is a SGLT2 inhibitor indicated to lower blood glucose level in T2D adjunct to diet & exercise, to reduce CV events & risk of ESKD and has received approval for the above indication on Sept 30, 2019

Click here to­ read full press release/ article | Ref: Business Wire | Image: Nau.ch

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post